Companies › TenNor Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Infectious disease; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TNP-2092 for injection (rifaquizinone for injection) Rifamycin-class antibiotic (rifaquizinone) | – | Phase 2 | Prosthetic Joint Infection (PJI) | Sep 2027 |
| Rifaquizinone (TNP-2092) Bacterial DNA-directed RNA polymerase inhibitor; Bacterial DNA gyrase inhibitor; Topoisomerase IV inhibitor | – | Phase 1 | Periprosthetic Joint Infection (PJI) | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06889701 | Rifaquizinone (TNP-2092) | Phase 1 | Periprosthetic Joint Infection (PJI) | Infectious disease | Jan 2027 |
| NCT07858916 | TNP-2092 for injection (rifaquizinone for injection) | Phase 2 | Prosthetic Joint Infection (PJI) | Infectious disease | Sep 2027 |
No annotated target.
–
Suzhou HepaThera Biotech TaiMed Biologics Amplexd Therapeutics Sano Chemicals Hyundai Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.